All News

In honor of CURE®’s 20th anniversary, here is a roundup of some of the major advancements in the world of cancer care, according to experts, patients and advocates.

The treatment and support that children with cancer receive has advanced over the past 20 years, but more progress to improve the cure rate is on the horizon.

When I experienced a sarcoma recurrence in 2017, I was given less than a 10% chance to live for five years. Now that I’ve surpassed that statistic and celebrated my five-year wedding anniversary, I’ve proven to myself that I’m not defined by cancer statistics.

When Sean Korbitz was a 20-year-old college student, his life trajectory changed with a rare cancer diagnosis, resulting in the removal of 40 tumors; fifteen years later, a new drug made him feel like a “medical miracle.”

Patients with non-muscle invasive bladder cancer who smoke should consider quitting to possibly improve health outcomes in survivorship, according to an expert.

Watch Dr. Jamile Shammo and Dr. John Mascarenhas answer questions about polycythemia vera during the CURE Educated Patient MPN Summit.

From eye removal to radiation damage, patients with uveal melanoma may face complications after treatment, although continued and new therapies may address these issues, an expert said.

Progression-free survival and overall response rates greatly improved in patients with CLL/SLL treated with Brukinsa compared with Imbruvica.

I was told I had the “good” type of breast cancer, but does such a thing even exist? I think not.

Sexual dysfunction is not less common in women with bladder cancer who undergo reproductive organ-sparing radical cystectomy, although more research is needed.

Watch Dr. John Mascarenhas, from the Icahn School of Medicine at Mount Sinai, discuss future treatments for polycythemia vera, during the CURE Educated Patient MPN Summit.

Patients with chronic lymphocytic leukemia tended to switch to another regimen or intensify their Calquence treatment quicker than those given Imbruvica, study results showed.

Newer drugs for kidney cancer have proven extremely effective but can cause unwanted symptoms that affect safety and quality of life.

From ballooning ankles to rashes, there were multiple chemotherapy side effects that I had to deal with — here’s how I did it.

Improvements may not be seen right away, but patients with non-metastatic breast cancer should stay compliant to practicing yoga to possibly improve quality of life, according to an expert.

Krazati was granted an accelerated approval for patients with KRAS G12C-mutant locally advanced or metastatic non-small cell lung cancer, according to the Food and Drug Administration.

Watch Dr. Jamile M. Shammo, from Northwestern University Feinberg School of Medicine, discuss current treatment options in polycythemia vera during the CURE Educated Patient MPN Summit.

During the holiday season, immunocompromised people, particularly patients with cancer, may have an increased risk for getting COVID-19. An expert shares tips on how to have safe and enjoyable family gatherings.

CURE® took a look at the most popular and practice-changing breast cancer news from 2022. Here’s what we found.

Men often decide to tough out their cancer alone, but tough guy Terry Bradshaw is starting to open up about his sometimes-rocky journey with the disease.

CURE®’s Multiple Myeloma Heroes® Award Program honors and gives thanks to those who have made it their mission to change the lives of patients with multiple myeloma.

Tecentriq was approved by the FDA for adults and children aged two years and older with advanced alveolar soft part sarcoma, a disease typically diagnosed in approximately 80 patients per year in the U.S.

Watch Dr. Aaron Gerds and Dr. Douglas Tremblay answer questions about essential thrombocythemia during the CURE Educated Patient MPN Summit.

Watch Dr. Douglas A. Tremblay, from Mount Sinai, discuss treatment for essential thrombocythemia during the CURE Educated Patient MPN Summit.

Watch Dr. Aaron T. Gerds, from Cleveland Clinic Taussig Cancer Institute, discuss essential thrombocythemia risk during the CURE Educated Patient MPN Summit.

Lifileucel, a personalized adoptive tumor-infiltrating lymphocyte therapy, showed promising responses in patients with pretreated melanoma, according to cohort findings from a recent clinical trial.

From fertility issues to oral side effects, cancer survivors may face health complications after treatment ends.

Once I got the hang of administering subcutaneous immunoglobulin, my life was so much easier, as I no longer had to undergo monthly IV infusions for my cancer-related compromised immune system.